FUJIFILM
sarcomaThis record tracks a ransomware attack claimed by the sarcoma group against FUJIFILM. It collects the publicly disclosed attack details — sector, location and timeline — as published on the operator's leak site and indexed by Breach House.
Window Zero
EXPOSURE GAPWindow Zero is the time the breach stayed in the open before anyone said so — the gap between when the attack was first discovered on the operator's leak site (t1) and when it was publicly disclosed (t2). The wider this window, the longer victims, staff and customers were exposed with no warning.
Attack Summary
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
Leak Screenshots
SAMPLEProof-of-breach screenshots the operator posted from the stolen data. Previews are redacted and locked — the originals are available on HaveIBeenRansom.